Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
561- ART/DHA,    Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo
- in-vivo, NA, NA
TumCG↓, CD4+↓, CD25+↓, FoxP3+↓, IL4↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
557- ART/DHA,    Artemisinin and Its Derivatives in Cancer Care
- Review, Var, NA
*BioAv↓, *BioAv↑, Apoptosis↑, EGFR↓, CD31↓, Ki-67↓, P53↓, TfR1/CD71↑, P-gp↓, PD-1↝,
555- ART/DHA,    Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action
- Review, NA, NA
STAT3↓,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
559- ART/DHA,    Artemisinin and its derivatives: a promising cancer therapy
- Review, NA, NA
ROS↑,
560- ART/DHA,    Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo
- in-vivo, NA, NA
IL4↓, CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓,
562- ART/DHA,    Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression
- in-vivo, NA, HeLa
CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓, PGE2↓, FOXP3↓, COX2↓,
563- ART/DHA,    Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10
- in-vitro, Colon, colon26 - in-vitro, CRC, RKO
TGF-β↓, IL10↓,
564- ART/DHA,  Cisplatin,    Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling
- in-vitro, NA, HN30
JAK2↓, STAT3↓, MMP2↓, MMP9↓, Mcl-1↓, Bcl-xL↓, cycD1/CCND1↓, VEGF↓, TumCCA↑, ChemoSen↑,
565- ART/DHA,    Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma
STAT↓, IL6↓, pro‑Casp3↝, Bcl-xL↝, survivin↝,
566- ART/DHA,  2DG,    Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
GlucoseCon↓, ATP↓, lactateProd↓, p‑S6↓, mTOR↓, GLUT1↓, Casp9↑, Casp8↑, Casp3↑, Cyt‑c↑, AIF↑, ROS↑,
569- ART/DHA,    Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3
- in-vitro, GBM, NA
TumCP↓, Apoptosis↑, TumCCA↑, Casp3↑, p‑Akt↓,
567- ART/DHA,    An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells
- in-vitro, Lung, BEAS-2B
NRF2↑, AP-1↑, NFAT↑,
568- ART/DHA,    Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity
- in-vitro, NA, MDA-MB-231 - in-vitro, NA, HeLa - in-vitro, NA, SkBr3 - in-vitro, NA, HCT116
Iron↝,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑, NRF2↓,
1079- ART/DHA,    Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2
- in-vitro, GC, BGC-823 - in-vitro, GC, HGC27 - in-vitro, GC, MGC803
TumCP↓, Apoptosis↑, COX2↓, BAX↑, Bcl-2↓, Casp3↑, Casp9↑, MMP↓,
1099- ART/DHA,    Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
- in-vitro, NA, NA
EMT↓, TumCI↓, STAT3↓, β-catenin/ZEB1↓,
1075- ART/DHA,    Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer
- in-vitro, Nor, L929
*TGF-β↓,
1074- ART/DHA,    Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells
- in-vitro, Nor, BV2
*TNF-α↓, *IL6↓, *MCP1↓, *NO↓, *iNOS↓, *IκB↑,
1026- ART/DHA,    Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
Ferroptosis↑, ROS↑, ERK↓, PD-L1↓,
957- ART/DHA,    Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels
- in-vitro, ESCC, KYSE150 - in-vitro, ESCC, KYSE170
TumCP↓, TumMeta↓, Glycolysis↓, N-cadherin↓, PKM2↓, Hif1a↓,
976- ART/DHA,    Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells
- in-vitro, BC, MCF-7
ERα/ESR1↓,
985- ART/DHA,    Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway
- in-vitro, Thyroid, TPC-1 - Human, NA, NA
XIST↓, Hif1a↓, Glycolysis↓, TumCCA↑, TumMeta↓,
2323- ART/DHA,    Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
PKM2↓, lactateProd↓, GlucoseCon↓, cycD1/CCND1↓, Bcl-2↓, MMP2↓, VEGF↓, Casp3↑, cl‑PARP↑, BAX↑, DNAdam↑, ROS↑,
2322- ART/DHA,    Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
- in-vitro, Melanoma, NA
TumCP↓, PKM2↓, LDHA↓, Glycolysis↓,
2321- ART/DHA,    Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
Pyro↑, PKM2↓, Casp8↑, Casp3↑, Warburg↓, TumCCA↑, Apoptosis↑,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,
2324- ART/DHA,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
PKM2↓, GLUT1↓, Glycolysis↓, Akt↓, mTOR↓, Hif1a↓, HK2↓, LDH↓, NF-kB↓,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,
2570- ART/DHA,    Discovery, mechanisms of action and combination therapy of artemisinin
- Review, Nor, NA
*BioAv↓, *Half-Life↓, *toxicity↓, *ROS↑, GSH↓, selectivity↑,
2575- ART/DHA,  docx,    Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC
- in-vitro, Lung, H23
ChemoSen↑, GPx4↓, ROS↑, Ferroptosis↑, eff↑,
2571- ART/DHA,    Cancer combination therapies with artemisinin-type drugs
- Review, Var, NA
AntiTum↑, ChemoSen↑, hepatoP↝,
2572- ART/DHA,  SRF,    Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
- in-vitro, AML, NA
CHOP↑, Mcl-1↓, ChemoSen↑, selectivity↑,
2573- ART/DHA,    Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells
- in-vitro, CRC, HCT116
eff↑,
2574- ART/DHA,    Artemisinin: A Promising Adjunct for Cancer Therapy
- Review, Var, NA
selectivity↑, eff↑,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
eff↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,
2577- ART/DHA,    Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
- Review, Var, NA
eff↑, TumCCA↑, BioAv↑, eff↑, ChemoSen↑,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
2580- ART/DHA,  VitC,    Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells
- in-vitro, AML, NA
eff↓, other↝, ROS↑, eff↓, eff↓,
2581- ART/DHA,  PB,    Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells
- in-vitro, AML, NA
eff↑, selectivity↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
eff↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,
2461- ASA,    Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
- Review, NA, NA
AntiAg↑, COX1↓, eff↑,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5416- ASA,    Cancer Incidence and Mortality With Aspirin in Older Adults
- Trial, Var, NA
Risk∅, OS∅,
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
5414- ASA,    Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Review, Var, NA
Risk↓, *toxicity↓, other↑, *COX1↓, TumCP↓, DNArepair↑, ChemoSen↑, other↓,
5413- ASA,    Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin
- Trial, Nor, NA
*cardioP↑, *other↝, *COX1↓, *TXA2↓,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,

Showing Research Papers: 801 to 850 of 5772
Prev Page 17 of 116 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5772

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   Ferroptosis↑, 4,   GPx4↓, 1,   GSH↓, 1,   Iron↝, 1,   i-Iron↓, 1,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↑, 12,  

Metal & Cofactor Biology ⓘ

TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMP↓, 1,   AMPK↑, 2,   cMyc↓, 3,   ECAR↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 5,   HK2↓, 1,   lactateProd↓, 3,   LDH↓, 1,   LDHA↓, 2,   PKM2↓, 6,   p‑S6↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 8,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Bcl-xL↝, 1,   Casp3↑, 6,   pro‑Casp3↝, 1,   Casp8↑, 2,   Casp9↑, 3,   p‑Chk2↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 4,   Mcl-1↓, 2,   Myc↓, 1,   necrosis↑, 1,   oncosis↑, 2,   p27↑, 1,   Pyro↑, 1,   survivin↓, 1,   survivin↝, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 2,   other↝, 3,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 3,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 2,   DNArepair↑, 1,   HR↓, 1,   p16↑, 1,   P53↓, 1,   cl‑PARP↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 3,   cycE1↓, 1,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   CREBBP↓, 1,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 2,   mTOR↓, 4,   mTOR↑, 1,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↑, 1,   PI3K↓, 1,   SOX2↓, 1,   STAT↓, 1,   STAT3↓, 3,   TumCG↓, 4,   Wnt/(β-catenin)↓, 2,   Wnt/(β-catenin)↑, 1,  

Migration ⓘ

AntiAg↑, 2,   AP-1↑, 1,   CD31↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 3,   ITGB1↑, 1,   Ki-67↓, 1,   LysoPr↑, 1,   MMP2↓, 4,   MMP9↓, 2,   N-cadherin↓, 2,   NCAM↑, 1,   NFAT↑, 1,   Slug↓, 1,   TGF-β↓, 2,   TIMP2↑, 1,   Treg lymp↓, 2,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 5,   TumMeta↓, 3,   Twist↓, 1,   Vim↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   Hif1a↓, 4,   KDR/FLK-1↓, 1,   NO↓, 1,   TXA2↓, 1,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 3,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 3,   CD4+↓, 3,   COX1↓, 2,   COX2↓, 2,   FOXP3↓, 1,   FoxP3+↓, 3,   IL1↓, 1,   IL10↓, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 2,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 3,   PD-1↝, 1,   PD-L1↓, 2,   PGE2↓, 3,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↑, 1,   Dose↝, 1,   eff↓, 3,   eff↑, 10,   RadioS↑, 1,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   ERα/ESR1↓, 1,   IL6↓, 2,   Ki-67↓, 1,   LDH↓, 1,   Myc↓, 1,   PD-L1↓, 2,   XIST↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   hepatoP↝, 1,   OS∅, 1,   Risk↓, 3,   Risk∅, 1,   toxicity↓, 1,  
Total Targets: 160

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 1,  

Migration ⓘ

AntiAg↑, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   TXA2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 3,   COX2↓, 1,   IL6↓, 1,   IκB↑, 1,   MCP1↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   Half-Life↓, 3,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   toxicity↓, 2,  
Total Targets: 23

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page